2025 Q2 -tulosraportti
199 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10 t sittenSmall technical analysis: Shows that it has cooled down and it's very important that Rsi is drastically down without volume or the price having fallen hardly at all. Bullish signal to go higher. Can quickly see 5.8 again for further upside. 5.38 must be broken too Bullish reset (RSI) RSI was previously very high (around 85–87), which showed extreme momentum. Now RSI has fallen to around 53–60 without the price having fallen much. This means that momentum has "cooled down" while the trend remains strong, which often allows for a new upward wave. — Trend and structure The price is still above EMA and SMA, and the chart still shows higher highs and higher lows. This confirms that the uptrend is still intact. — Aroon (trend strength) Aroon is high (75–83), which means that the stock still makes new highs relatively often and that the trend strength is still strong. RSI has done a bullish reset • The trend is still up • Aroon shows strong trend • A possible trigger is around 5.38 If resistance is broken, the stock can technically open for a new upward wave in the trend. 📈
·8 t sitten · MuokattuSuper, thanks for the update Frankie! Catoman hereby on mute, strange behavior. 🤨 In the same breath, THANKS 🙏 for all the good factual posts that explain the fundamentals in the results Circio has shown so far, as well as here the technical aspects regarding where we are! By far the most active forum I have seen here on NN😊.
·13 t sittenAfter the rapid increase due to FOMO, we should expect it to seek down towards price 3.5-3.8 within next week.·8 t sittenNo reason to waste energy on Stock.dk, his own declaration of content says it all, 'free fantasy '. Mute, and move on 🤗
·14 t sittenPodcast What is it that people expect to be told in the podcast that is not already known, which makes people so expectant for that podcast? Hope it turns out well but can't quite figure out what it could be.- ·15 t sitten · MuokattuThis has nothing to do with "recreating". EDW has stated that it is in a CNS disease that Big P struggled with its results and that they therefore believe in circVec as a solution. Mao their own (mRNA?) is not good enough. Everything is carried out at Circio. BP pays the bill for the development of the cirVec construct (BP's "medicine") in this disease model and the in vivo study with this variant. In addition, Circio has its own internal CNS study where reporter data will only come now in Q2 and here EDW has stated that it looks good, just as good as in heart and eye data at the same stage. That bodes very well for the Feasibility Study. Personally, I believe they have already done a CNS study, this started early in the autumn, and that was why they got the agreement with BP in Nov on that basis. What comes in Q2 is the quality assurance of CNS and therefore EDW probably has a good basis for suggesting that it looks good.
·18 t sittenI want to bring some clarity to this feasibility study, which is one of the reasons the stock has gone up a lot lately, and has the potential to go up more. It is therefore one of the largest Big Pharma companies in the world that is paying Circio to replicate its results either in its own laboratory or possibly under their supervision, with their tests and systems. So why are they doing this? The purpose is to build trust and ensure that the studies are correct before a license or co-development agreement. In other words, such an agreement is veeeery likely. Such an agreement usually entails an upfront payment and then Milestone payments as development progresses or products are rolled out, before eventual royalties or acquisition. The upfront payment depends on whether it is a platform that can be used for multiple therapies/diseases (like Circvec) and whether the agreement is exclusive. The upfront payment could be 10-20 mill USD. With expected Milestone payments, it could easily justify a value of 1.5 billion USD for the Circvec platform in the preclinical phase, i.e., when the agreement is signed. This is according to chatgpt with other comparable companies. But if they succeed in clinical trials, the value shoots up many billions. And if they bring finished products to market, we're talking many, many billions. But this is possibly a bit further down the road. Then there are pitfalls. Perhaps they won't get the same results in the feasibility study. Perhaps Circvec doesn't work the same way in humans as in mice. One doesn't know yet. But it is an incredibly exciting stock with great potential to do 10x within a couple of years.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
199 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenSmall technical analysis: Shows that it has cooled down and it's very important that Rsi is drastically down without volume or the price having fallen hardly at all. Bullish signal to go higher. Can quickly see 5.8 again for further upside. 5.38 must be broken too Bullish reset (RSI) RSI was previously very high (around 85–87), which showed extreme momentum. Now RSI has fallen to around 53–60 without the price having fallen much. This means that momentum has "cooled down" while the trend remains strong, which often allows for a new upward wave. — Trend and structure The price is still above EMA and SMA, and the chart still shows higher highs and higher lows. This confirms that the uptrend is still intact. — Aroon (trend strength) Aroon is high (75–83), which means that the stock still makes new highs relatively often and that the trend strength is still strong. RSI has done a bullish reset • The trend is still up • Aroon shows strong trend • A possible trigger is around 5.38 If resistance is broken, the stock can technically open for a new upward wave in the trend. 📈·8 t sitten · MuokattuSuper, thanks for the update Frankie! Catoman hereby on mute, strange behavior. 🤨 In the same breath, THANKS 🙏 for all the good factual posts that explain the fundamentals in the results Circio has shown so far, as well as here the technical aspects regarding where we are! By far the most active forum I have seen here on NN😊.
- ·13 t sittenAfter the rapid increase due to FOMO, we should expect it to seek down towards price 3.5-3.8 within next week.·8 t sittenNo reason to waste energy on Stock.dk, his own declaration of content says it all, 'free fantasy '. Mute, and move on 🤗
- ·14 t sittenPodcast What is it that people expect to be told in the podcast that is not already known, which makes people so expectant for that podcast? Hope it turns out well but can't quite figure out what it could be.
- ·15 t sitten · MuokattuThis has nothing to do with "recreating". EDW has stated that it is in a CNS disease that Big P struggled with its results and that they therefore believe in circVec as a solution. Mao their own (mRNA?) is not good enough. Everything is carried out at Circio. BP pays the bill for the development of the cirVec construct (BP's "medicine") in this disease model and the in vivo study with this variant. In addition, Circio has its own internal CNS study where reporter data will only come now in Q2 and here EDW has stated that it looks good, just as good as in heart and eye data at the same stage. That bodes very well for the Feasibility Study. Personally, I believe they have already done a CNS study, this started early in the autumn, and that was why they got the agreement with BP in Nov on that basis. What comes in Q2 is the quality assurance of CNS and therefore EDW probably has a good basis for suggesting that it looks good.
- ·18 t sittenI want to bring some clarity to this feasibility study, which is one of the reasons the stock has gone up a lot lately, and has the potential to go up more. It is therefore one of the largest Big Pharma companies in the world that is paying Circio to replicate its results either in its own laboratory or possibly under their supervision, with their tests and systems. So why are they doing this? The purpose is to build trust and ensure that the studies are correct before a license or co-development agreement. In other words, such an agreement is veeeery likely. Such an agreement usually entails an upfront payment and then Milestone payments as development progresses or products are rolled out, before eventual royalties or acquisition. The upfront payment depends on whether it is a platform that can be used for multiple therapies/diseases (like Circvec) and whether the agreement is exclusive. The upfront payment could be 10-20 mill USD. With expected Milestone payments, it could easily justify a value of 1.5 billion USD for the Circvec platform in the preclinical phase, i.e., when the agreement is signed. This is according to chatgpt with other comparable companies. But if they succeed in clinical trials, the value shoots up many billions. And if they bring finished products to market, we're talking many, many billions. But this is possibly a bit further down the road. Then there are pitfalls. Perhaps they won't get the same results in the feasibility study. Perhaps Circvec doesn't work the same way in humans as in mice. One doesn't know yet. But it is an incredibly exciting stock with great potential to do 10x within a couple of years.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
199 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenSmall technical analysis: Shows that it has cooled down and it's very important that Rsi is drastically down without volume or the price having fallen hardly at all. Bullish signal to go higher. Can quickly see 5.8 again for further upside. 5.38 must be broken too Bullish reset (RSI) RSI was previously very high (around 85–87), which showed extreme momentum. Now RSI has fallen to around 53–60 without the price having fallen much. This means that momentum has "cooled down" while the trend remains strong, which often allows for a new upward wave. — Trend and structure The price is still above EMA and SMA, and the chart still shows higher highs and higher lows. This confirms that the uptrend is still intact. — Aroon (trend strength) Aroon is high (75–83), which means that the stock still makes new highs relatively often and that the trend strength is still strong. RSI has done a bullish reset • The trend is still up • Aroon shows strong trend • A possible trigger is around 5.38 If resistance is broken, the stock can technically open for a new upward wave in the trend. 📈·8 t sitten · MuokattuSuper, thanks for the update Frankie! Catoman hereby on mute, strange behavior. 🤨 In the same breath, THANKS 🙏 for all the good factual posts that explain the fundamentals in the results Circio has shown so far, as well as here the technical aspects regarding where we are! By far the most active forum I have seen here on NN😊.
- ·13 t sittenAfter the rapid increase due to FOMO, we should expect it to seek down towards price 3.5-3.8 within next week.·8 t sittenNo reason to waste energy on Stock.dk, his own declaration of content says it all, 'free fantasy '. Mute, and move on 🤗
- ·14 t sittenPodcast What is it that people expect to be told in the podcast that is not already known, which makes people so expectant for that podcast? Hope it turns out well but can't quite figure out what it could be.
- ·15 t sitten · MuokattuThis has nothing to do with "recreating". EDW has stated that it is in a CNS disease that Big P struggled with its results and that they therefore believe in circVec as a solution. Mao their own (mRNA?) is not good enough. Everything is carried out at Circio. BP pays the bill for the development of the cirVec construct (BP's "medicine") in this disease model and the in vivo study with this variant. In addition, Circio has its own internal CNS study where reporter data will only come now in Q2 and here EDW has stated that it looks good, just as good as in heart and eye data at the same stage. That bodes very well for the Feasibility Study. Personally, I believe they have already done a CNS study, this started early in the autumn, and that was why they got the agreement with BP in Nov on that basis. What comes in Q2 is the quality assurance of CNS and therefore EDW probably has a good basis for suggesting that it looks good.
- ·18 t sittenI want to bring some clarity to this feasibility study, which is one of the reasons the stock has gone up a lot lately, and has the potential to go up more. It is therefore one of the largest Big Pharma companies in the world that is paying Circio to replicate its results either in its own laboratory or possibly under their supervision, with their tests and systems. So why are they doing this? The purpose is to build trust and ensure that the studies are correct before a license or co-development agreement. In other words, such an agreement is veeeery likely. Such an agreement usually entails an upfront payment and then Milestone payments as development progresses or products are rolled out, before eventual royalties or acquisition. The upfront payment depends on whether it is a platform that can be used for multiple therapies/diseases (like Circvec) and whether the agreement is exclusive. The upfront payment could be 10-20 mill USD. With expected Milestone payments, it could easily justify a value of 1.5 billion USD for the Circvec platform in the preclinical phase, i.e., when the agreement is signed. This is according to chatgpt with other comparable companies. But if they succeed in clinical trials, the value shoots up many billions. And if they bring finished products to market, we're talking many, many billions. But this is possibly a bit further down the road. Then there are pitfalls. Perhaps they won't get the same results in the feasibility study. Perhaps Circvec doesn't work the same way in humans as in mice. One doesn't know yet. But it is an incredibly exciting stock with great potential to do 10x within a couple of years.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt